Drugs in lactation Source: LactMed

Phosphorus P 32 and Breastfeeding

Summary of use during lactation

Information in this record refers to the use of phosphorus P 32 as a therapeutic agent. No information is available on the use of phosphorus P 32 during breastfeeding. Use of phosphate P 32 as a skin patch to treat skin cancers poses no risk to breastfed infants after removal of the patch from the mother's skin

Drug levels in milk and infant serum

Phosphorus P 32 decays by beta emission with an energy of 1.709 MeV and a half-life of 14.3 days.[1]

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information was not found as of the revision date.

References

  1. MountfordPJ WellsCP HallFM Potential radiation dose to a breast-fed infant following administration of sodium 32P-phosphate to the mother. Nucl Med Commun 1984 5 473 6 6531156 PubMed

Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.

Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.